Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. (September 2013)

• Record Type: Journal Article
• Authors: Labrador-Horrillo, Moises; Valero, Antonio; Velasco, Manuel; Jáuregui, Ignacio; Sastre, Joaquin; Bartra, Joan; Silvestre, Juan Francisco; Ortiz de Frutos, Javier; Gimenez-Arnau, Ana; Ferrer, Marta
• Is Part Of: Expert opinion on biological therapy. Volume 13:Number 9(2013:Sep.)
• Page Start: 1225
• Page End: 1228
• Publication Date: 2013-09
• Subjects: chronic spontaneous urticaria -- chronic urticaria -- CSU -- omalizumab; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1517/14712598.2013.822484
• Languages: English
• ISSNs: 1471-2598

Abstract

Abstract : Objective: To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment. Methods: A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012. Results: Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported. Conclusions: Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life.